Compare Gilead Sciences, Inc. (GILD) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Invesco Ltd. — how do they compare? Gilead Sciences, Inc. trades at $131.69 (market cap $163.51B), while Invesco Ltd. trades at $30.45 (market cap $13.43B). The key difference: Gilead Sciences, Inc. is far larger — about 12.2× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (2.84%). Which is the better fit depends on your goals.
| GILD | IVZ | |
|---|---|---|
Market Cap | $163.51B | $13.43B |
Sector | Health | Financials |
52-Week High | $155.80 | $30.30 |
52-Week Low | $108.22 | $16.88 |
Enterprise Value | $178.05B | $23.68B |
Dividend Yield | 2.49% | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Invesco (IVZ) trades at $30.50, up 6.16% in the past 24 hours, with a bullish technical signal from moving averages. The company reported mixed earnings, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Revenue grew to $6.38 billion in 2025, though net income remained negative at -$281.70 million. Analyst consensus is divided with 12 buys and 16 holds, targeting $30.50 on average. Recent news highlights dividend declarations and AUM growth to $2.47 trillion as of June 2026.
The outlook for IVZ is cautiously optimistic, supported by strong cash flow from operations and upward earnings revisions. Key risks include persistent negative profit margins and competitive pressures in asset management. Upside potential hinges on execution improvements and market sentiment shifts, with the current price near the consensus target suggesting limited near-term movement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
